DLB with Visual Hallucinations, Delusions, and Apathy: When Cholinesterase Inhibitors Have Not Achieved Adequate Control
This protocol covers Dementia with Lewy bodies presenting with neuropsychiatric features — visual hallucinations, delusions, apathy, and/or behavioral disturbance — specifically in patients where first-line management has not produced sufficient symptom control.
Previous Line — Goals Not Met
Cholinesterase inhibitors were used with the aim of reducing apathy and improving visual hallucinations and delusions. When these targets remain substantially unmet — neuropsychiatric symptoms persist at a level that impairs care — escalation to the next structured approach is warranted.
Next-Line Approach
The next step involves a carefully selected antipsychotic agent, used only when truly unavoidable, given the attendant mortality risks in dementia and the elevated risk of a serious sensitivity reaction specific to DLB.
The full protocol details agent selection, conditions for use, and the complete management algorithm — see below.
References
DOI: 10.1212/WNL.0000000000004058
CHEIs may produce substantial reduction in apathy and improve visual hallucinations and delusions in DLB.
The use of antipsychotics for the acute management of substantial behavioral disturbance, delusions, or visual hallucinations comes with attendant mortality risks in patients with dementia, and particularly in the case of DLB they should be avoided whenever possible, given the increased risk of a serious sensitivity reaction.
Low-dose quetiapine may be relatively safer than other antipsychotics and is widely used, but a small placebo-controlled clinical trial in DLB was negative.
There is a positive evidence base for clozapine in PD psychosis, but efficacy and tolerability in DLB have not been established.
Newer drugs targeting the serotonergic system, such as pimavanserin, may be alternatives, but controlled clinical trial data in DLB are needed.
View source ↗